Cross-species lytic bacteriophage for carbapenem-resistant pseudomonas aeruginosa and application of cross-species lytic bacteriophage
By providing a transgenic lytic phage GNRTLP10 targeting the carbapenem-resistant Pseudomonas aeruginosa, the treatment difficulties caused by the high resistance of the bacteria were solved, and efficient lysis and inhibition effects were achieved, and it also had a related bacterial rate. The significant inhibitory effect provides new prevention and control measures.
Patent Information
- Application Number
- CN202411205908.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-26
AI Technical Summary
The emergence of carbapenem-resistant Pseudomonas aeruginosa makes its treatment more difficult. The prior art is difficult to effectively prevent and treat infections caused by such bacteria, especially due to their high drug resistance and easy formation of biological membranes, resulting in the treatment effect of infection. Not good.
A transgenic lytic phage GNRTLP10 targeting carbapenem-resistant Pseudomonas aeruginosa is provided, which can efficiently cleave and inhibit this bacteria and other related bacteria, including Pseudomonas putida and fluorescent Pseudomonas Bacteria and PseudoAlternative Monassium dermatosis are used to prepare therapeutic, preventive and antibacterial agents.
The lysis rate of phage GNRTLP10 on 55 strains of carbapenem-resistant Pseudomonas aeruginosa is as high as 98.18%, and it continues to inhibit its growth within 48 hours. It has good fermentation titers and antibacterial effects across species, and is used to other types. The related bacteria also showed significant cleavage effects, providing effective prevention and treatment methods.
Smart Images

Figure BDA0005019016400000041 
Figure BDA0005019016400000051 
Figure BDA0005019016400000061
Abstract
Description
Technical Field
[0001] The present invention relates to the field of microbial technology, and in particular to a cross-species lytic phage targeting carbapenem-resistant Pseudomonas aeruginosa and an application thereof. Background Art
[0002] Pseudomonas aeruginosa is a Gram-negative bacterium, an aerobic, long rod-shaped bacterium with only unidirectional motility. It is a conditional pathogen of opportunistic infection in animals and plants, with the characteristics of easy colonization, easy mutation and multi-drug resistance. After infection, the pus and exudate of the diseased parts of animals are green.
[0003] Pseudomonas aeruginosa is one of the most common pathogens of difficult-to-treat lower respiratory tract infections. Due to its severe drug resistance and easy formation of biofilms, especially the emergence of carbapenem-resistant strains in the past 10 years, its treatment has become more difficult; the World Health Organization has released its updated "2024 List of Priority Bacterial Pathogens", including 15 drug-resistant bacteria, among which carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global problem that needs to be taken seriously. Researchers have shown that carbapenemase-producing CRPA isolates are more resistant to meropenem than non-carbapenemase-producing CRPA isolates, and have a higher resistance rate to other antipseudomonal drugs. In addition, patients with CRPA infection that produces carbapenemase have a higher 30-day mortality rate, even after adjusting for confounding factors (https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC10016089 / ).
[0004] The abuse of antibiotics is the main reason for the proliferation of drug-resistant strains today. The state encourages the development of safe, green, and targeted alternative antibiotic products for bacterial diseases. Bacteriophage is a very green, healthy, non-residue, sustainable, and highly targeted bacterial virus. Based on this, the present invention provides a cross-species lytic phage for carbapenem-resistant Pseudomonas aeruginosa (CRPA) and its application. Summary of the invention
[0005] In order to prevent infection problems caused by Pseudomonas aeruginosa and carbapenem-resistant Pseudomonas aeruginosa and reduce the health risks caused by the problems, one of the objects of the present invention is to provide a phage against carbapenem-resistant Pseudomonas aeruginosa, and the deposit number of the phage GNR TL P10 is CCTCC NO: M 20241461.
[0006] The second object of the present invention is to provide the use of bacteriophage GNRTLP10 in inhibiting Pseudomonas. The bacteriophage provided by the present invention has a lytic effect on Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and Pseudomonas nigrofaciens.
[0007] In order to achieve the above object, the present invention adopts the following technical measures:
[0008] Acquisition of a cross-species lytic phage against carbapenem-resistant Pseudomonas aeruginosa (CRPA):
[0009] The applicant isolated a Pseudomonas aeruginosa phage GRNTLP10 from sewage in Jiangsu Province. The phage was deposited in the China Center for Type Culture Collection on July 3, 2024, and the classification name was: Pseudomonas aeruginosaphage GRNTLP10. The deposit address is: Wuhan University, Wuhan, China; the deposit number is CCTCC NO: M20241461.
[0010] The protection scope of the present invention also includes:
[0011] A compound comprises a Pseudomonas aeruginosa phage with a deposit number of CCTCC NO: M20241461.
[0012] The use of the bacteriophage or compound in the preparation of a drug for treating or preventing Pseudomonas infection, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas melanogenes.
[0013] The use of the above-mentioned bacteriophage or compound in the preparation of a pseudomonas antibacterial agent, wherein the pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudoalteromonas nigrifaciens.
[0014] The use of the above-mentioned bacteriophage or compound in non-therapeutic in vitro inhibition of Pseudomonas, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas melanogenes.
[0015] The use of the bacteriophage or the compound in preparing a feed additive for antagonizing Pseudomonas, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas melanogenes.
[0016] In the above application, the Pseudomonas aeruginosa is preferably carbapenem-resistant Pseudomonas aeruginosa.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] 1. The lysis spectrum of bacteriophage GRNTLP10 against carbapenem-resistant Pseudomonas aeruginosa is wide, and the lysis rate of 55 strains of carbapenem-resistant Pseudomonas aeruginosa is as high as 98.18%, which can effectively prevent and treat the infection of Pseudomonas aeruginosa and carbapenem-resistant Pseudomonas aeruginosa.
[0019] 2. The Pseudomonas aeruginosa phage GRNTLP10 is a phage with cross-genus and species lysis ability. In addition to being highly effective against carbapenem-resistant Pseudomonas aeruginosa, it also has lysis effects on Pseudomonas putida, Pseudomonas fluorescens, and Pseudomonas nigrofaciens. The lysis rate for 10 strains of Pseudomonas putida was 80%; the lysis rate for 10 strains of Pseudomonas fluorescens was 70%; and the lysis rate for 5 strains of Pseudomonas nigrofaciens was 100%.
[0021] 3. The bacteriophage GRNTLP10 has a sustained antibacterial effect on carbapenem-resistant Pseudomonas aeruginosa. Within 48 hours, it effectively inhibits the growth of carbapenem-resistant Pseudomonas aeruginosa, and its OD600 value is maintained at 0.01-0.05.
[0022] 4. The phage has a good fermentation titer. At the optimal multiplicity of infection (MOI = 0.1), the fermentation titer of 100mL system can reach 2.5*10 10 pfu / mL; under the 6L amplification process system, its fermentation titer is 3.1*10 10 pfu / mL. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a plaque of Pseudomonas aeruginosa phage GRNTLP10.
[0024] Figure 2 The titer of Pseudomonas aeruginosa phage GRNTLP10 under different infection multiplicity conditions.
[0025] Figure 3 The inhibitory effect of Pseudomonas aeruginosa phage GRNTLP10 on simultaneous infection of multiple carbapenem-resistant Pseudomonas aeruginosa.
[0026] Figure 4 Schematic diagram of the fermentation dynamics of Pseudomonas aeruginosa phage GRNTLP10 in a 10L system.
[0027] Figure 5 The therapeutic effect of Pseudomonas aeruginosa phage GRNTLP10 on grouper infected with carbapenem-resistant Pseudomonas aeruginosa. DETAILED DESCRIPTION
[0028] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.
[0029] Embodiment 1:
[0030] Isolation and Purification of Pseudomonas aeruginosa Phage GRN TLP10
[0031] 150 sewage samples were collected from a water body in Jiangsu Province. Each sample was centrifuged at 6000 rpm for 5 min. The supernatant was sterilized with a 0.22 μm filter. 20 mL of the filtrate was mixed with 1 mL of Pseudomonas aeruginosa (concentration of about 1×10 7 CFU / mL) were mixed evenly, and after standing for 15 minutes, the culture was shaken at 200 rpm in a 37°C shaker for overnight fermentation. The fermentation broth was centrifuged at 6000 rpm for 10 minutes, the supernatant was sterilized with a 0.22 μm filter, and 100 μL of the filtrate was mixed with 300 μL of Pseudomonas aeruginosa (concentration was about 1×10 8 CFU / mL) and mix well, add TSB semi-solid (containing 0.65% agar), gently invert and pour on the TSA bottom plate, and after solidification, place the culture dish in a 37°C incubator for overnight culture. Pick up the transparent and bright plaque spots, shake and desorb in 1mL SM liquid, and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, inoculate it in 5mL TSB liquid culture medium, add 500μL of the corresponding host Pseudomonas aeruginosa bacterial liquid and mix well, shake and culture at 200rpm overnight at 37°C, centrifuge at 6000rpm for 10min, take the supernatant and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, and observe the plaque morphology by double-layer plate method. After repeating the operation 3-5 times, plaques of uniform shape and size can be obtained.
[0032] A strain of Pseudomonas aeruginosa phage GRNTLP10 was isolated from the water sample. Figure 1 As shown, the plaques formed by it and the host bacteria are transparent, round, and 1.0 mm in diameter. The phage has been deposited in the China Center for Type Culture Collection on July 3, 2024, with the classification name: Pseudomonas aeruginosa phage GRN TLP10, address: Wuhan University, Wuhan, China, and the deposit number: CCT CC NO: M 20241461.
[0033] Embodiment 2:
[0034] Determination of the titer of Pseudomonas aeruginosa phage GRN TLP10 under different infection multiplicity conditions:
[0035] The host bacteria of Pseudomonas aeruginosa phage GRNTLP10, Pseudomonas aeruginosa NJ001, was inoculated into an EP tube with 3 mL of TSB and cultured at 37°C for 5-8 hours to obtain NJ001 bacterial solution. The bacterial solution was inoculated into 100 mL of TSB medium at a 3% inoculum. When NJ001 grew to the initial logarithmic phase, phage GRNTLP10 was inoculated and the infection was carried out according to different multiplicity of infection (MOI; MOI = number of phages / number of bacteria, see Figure 2 ), each experiment was performed in triplicate. The cells were cultured in a 37°C shaker at 200 rpm for 12 h.
[0036] Results Figure 2 When MOI = 0.1, the fermentation titer reached a maximum of 2.5 × 10 10 PFU / mL.
[0037] Embodiment 3:
[0038] Host range of lytic carbapenem-resistant Pseudomonas aeruginosa by bacteriophage GRN TLP10
[0039] The experiment selected 55 carbapenem-resistant Pseudomonas aeruginosa from different sources, including 16 strains from Wuhan, 12 strains from Nanjing, 13 strains from Shanghai, 7 strains from Beijing, and 7 strains from Guangzhou; carbapenem-resistant Pseudomonas aeruginosa were inoculated into 3mL TSB EP tubes, and shaken at 37℃ and 200rpm overnight to obtain Pseudomonas aeruginosa bacterial liquid; prepare a sufficient amount of TSA bottom plate, mix 0.5ml Pseudomonas aeruginosa bacterial liquid with 6mL TSB semi-solid medium (containing 0.65% agar) at about 50℃, and slowly spread it on the TSA bottom plate; after the plate medium solidified to room temperature, take the titer of 1×10 8 5 μL of phage GRNTLP10 with a concentration of PFU / ml was dropped onto the plate, and after air drying, the plate was inverted and placed in a 37°C constant temperature biochemical incubator for about 8 hours, and the results were observed. Each group of experiments was repeated 3 times.
[0040] As shown in Table 1, phage GRNTLP10 can lyse 54 of the 55 carbapenem-resistant Pseudomonas aeruginosa, with a lysis rate of 98.18%. The experimental results confirm that this phage has a very outstanding effect in inhibiting carbapenem-resistant Pseudomonas aeruginosa, and has great value for the prevention, control and treatment of carbapenem-resistant Pseudomonas aeruginosa in the future.
[0041] Table 1 Lysis effect of bacteriophage GRN TLP10 on carbapenem-resistant Pseudomonas aeruginosa
[0042]
[0043]
[0044] Note: “-” indicates no lysis, and “+” indicates lysis.
[0045] Embodiment 4:
[0046] The lysis range of bacteriophage GRN TLP10 on other host species:
[0047] Ten strains of Pseudomonas putida (PP), ten strains of Pseudomonas fluorescens (PF) and five strains of Pseudoalteromonas nigrifaciens (PN) were selected for the experiment; the hosts were inoculated into 3 mL of TSB EP tubes, and shaken at 37°C and 200 rpm overnight to obtain host bacterial liquid; sufficient TSA bottom plates were prepared, 0.5 mL of host bacterial liquid was mixed with 6 mL of TSB semi-solid medium (containing 0.65% agar) at about 50°C, and slowly spread on the TSA bottom plate; after the plate medium solidified to room temperature, the titers of 1×10 8 5 μL of phage GRNTLP10 with a concentration of PFU / ml was dropped onto the plate, and after air drying, the plate was inverted and placed in a 37°C constant temperature biochemical incubator for about 8 hours, and the results were observed. Each group of experiments was repeated 3 times.
[0048] As shown in Table 2, the bacteriophage GRNTLP10 can lyse 8 of 10 strains of Pseudomonas putida with a lysis rate of 80%, lyse 7 of 10 strains of Pseudomonas fluorescens with a lysis rate of 70%, and lyse 5 of 5 strains of Pseudomonas putida with a lysis rate of 100%; the experimental results confirm that this bacteriophage has a lysis effect on Pseudomonas putida, Pseudomonas fluorescens and Pseudomonas melanogenes, and has great value for the prevention, control and treatment of one or more infection problems of Pseudomonas putida, Pseudomonas fluorescens and Pseudomonas melanogenes in the future.
[0049] Table 2 Lysis range of phage GRNTLP10 against other host species
[0050]
[0051] Note: “-” indicates no lysis, and “+” indicates lysis.
[0052] Embodiment 5:
[0053] Antibacterial effect of bacteriophage GRN TLP10 on simultaneous infection of multiple carbapenem-resistant Pseudomonas aeruginosa
[0054] Two carbapenem-resistant Pseudomonas aeruginosa strains, NJ001 and SH001, were selected for the experiment; the hosts were inoculated in 3 mL of TSB EP tubes, respectively, and shaken at 37 ° C and 200 rpm overnight to obtain host bacterial liquid; the above host bacterial liquid was inoculated, and the host concentration and phage concentration were adjusted. The experimental settings are shown in Table 3 below, and each group of experiments was repeated 3 times.
[0055] Table 3 Experimental settings
[0056]
[0057] Note: The experimental groups were set up with MOI=1, the experimental culture temperature was 37°C, the amplitude was 150rpm, and the bacterial concentration OD was detected at 2h, 4h, 6h, 8h, 12h, 18h, 24h, 30h, 36h, 42h, and 48h in each group of experiments. 600 .
[0058] The experimental results are as follows Figure 3 As shown in the results, the addition of phage GRNTLP10 and carbapenem-resistant Pseudomonas aeruginosa groups can effectively inhibit the growth of carbapenem-resistant Pseudomonas aeruginosa, whether it is a single host or two hosts, its OD600 value can be suppressed between 0.01-0.05, which is in sharp contrast to the positive group. The phage group can effectively inhibit the growth of carbapenem-resistant Pseudomonas aeruginosa within 48 hours, indicating that it has sustained antibacterial ability. In the future, effective phage resources can be provided to deal with the problem of infection with one carbapenem-resistant Pseudomonas aeruginosa or two carbapenem-resistant Pseudomonas aeruginosa.
[0059] Embodiment 6:
[0060] Fermentation preparation of Pseudomonas aeruginosa phage GRN TLP10:
[0061] A single colony of Pseudomonas aeruginosa NJ001 was picked from the plate, inoculated into 3 mL of TSB medium, and cultured at 37°C and 200 rpm for 10 h to obtain the host bacterial solution. The bacterial suspension was inoculated into 180 mL of TSB medium at a 3% inoculum, and cultured at 37°C and 150 rpm until the early logarithmic phase, and the bacterial solution OD600 value was 0.01.
[0062] The industrial fermentation is a 10L fermentation tank, the fermentation system is 6L, the medium used is TSB, the initial pH value is 7.4, the flame method is used to inoculate Pseudomonas aeruginosa at a 1% inoculation amount, and the phage GRNTLP10 is added to the fermentation system at the optimal infection condition MOI=0.1. Sterile air is introduced during the fermentation process, and 3‰ defoamer is added. The fermentation preparation time is 12h. Since the start of fermentation, 20ml of fermentation liquid is taken from the sampling port in a sterile container at 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, and 12h, and centrifuged at 6000rpm for 10min. The supernatant is sterilized through a 0.22μm microporous filter membrane to obtain a filtrate containing phage and its titer is determined. The method is referred to Example 2.
[0063] After the fermentation is completed, the entire mixed solution of phage and host bacteria is taken out from the sampling port and placed in a sterile container, centrifuged at 6000 rpm for 10 min, and the supernatant is filtered through a vacuum pump into a sterile filter device to obtain the phage fermentation solution and stored at 4°C.
[0064] Depend on Figure 4 It can be seen that the titer of Pseudomonas aeruginosa phage GRNTLP10 reached a maximum of 3.1×10 10 PFU / mL, in the period of 5h to 12h, the titer is stable at 10 10 PFU / mL; The results show that it is feasible to use fermentation method for industrial production of bacteriophages, which provides effective reference data for the preparation of bacteriophage products.
[0065] Embodiment 7:
[0066] Therapeutic effect of Pseudomonas aeruginosa phage GRNTLP10 on grouper infected with carbapenem-resistant Pseudomonas aeruginosa
[0067] The experimental setup is as follows:
[0068] (1) Experimental fish preparation: Healthy pearl grouper of uniform size was temporarily maintained in a recirculating seawater aquaculture system, and the aquaculture water temperature was controlled at about 18°C. 50 pearl groupers were randomly divided into 5 groups, with 10 fish in each group, and PBS was used as the negative control group.
[0069] (2) Preparation of bacterial suspension: Carbapenem-resistant Pseudomonas aeruginosa NJ001 strain was inoculated in TSB liquid and cultured to the logarithmic growth phase (37°C, 200 rpm), and the bacterial suspension was diluted to the corresponding concentration with sterile PBS buffer.
[0070] (3) Virus challenge: The infection was carried out by immersion. During the experiment, the concentration of the carbapenem-resistant Pseudomonas aeruginosa NJ001 strain was 1*10 6cfu / mL, and the negative control was immersed in the same volume of sterile PBS buffer for 24 h.
[0071] (4) Treatment: Treatment was performed 24 h after challenge. The treatment groups were divided into a phage treatment group (GRNTLP10) and an antibiotic treatment group (meropenem, doxycycline). Antibiotic treatment was performed according to the instructions for use. The phage treatment concentration was MOI = 1 for immersion treatment (MOI = 1 is equivalent to a bacterial solution concentration of 1*10 6 The survival status of the fish was observed and recorded, and the survival rate was recorded every day, and the observation and recording were continued until the 10th day after infection.
[0072] The specific experimental settings are shown in Table 4.
[0073] Table 4 Animal experiment groups
[0074] serial number Experimental Grouping Remark 1 Blank Group Normal feeding 2 Anti-virus group Bathing to treat NJ001, no treatment 3 Phage therapy group Bath treatment with NJ001, followed by phage (GRNTLP10) bath treatment 24 hours later 4 Antibiotic treatment group 1 Bath treatment with NJ001, followed by antibiotic (meropenem) bath treatment 24 hours later 5 Antibiotic treatment group 2 Bath treatment with NJ001, followed by antibiotic (doxycycline) bath treatment 24 hours later
[0075] The experimental results are as follows Figure 5 As shown, the survival rate of the phage treatment group was 90%, the survival rate of the antibiotic group (meropenem) was 40%, the survival rate of the antibiotic group (doxycycline) was 80%, the survival rate of the virus attack group was 0%, and the survival rate of the blank group was 100%. The experiment shows that phage has obvious advantages over antibiotic treatment, and has certain advantages as a biological product for reducing and replacing antibiotics in the future, providing new methods and ideas for the prevention and treatment of carbapenem-type Pseudomonas aeruginosa in the future.
[0076] This embodiment shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.
[0077] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. A Pseudomonas aeruginosa phage Pseudomonas aeruginosa The phage GRNTLP10 is deposited as CCTCC NO: M20241461.
2. A compound comprising a Pseudomonas aeruginosa phage with a deposit number of CCTCC NO: M20241461.
3. Use of the bacteriophage according to claim 1 or the compound according to claim 2 in the preparation of a medicament for treating or preventing Pseudomonas infection, wherein the Pseudomonas is Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), Pseudomonas putida ( Pseudomonas putida ), Pseudomonas fluorescens ( Pseudomonas fluorescens ) and / or Pseudomonas melanogenes ( Pseudoalteromonas nigrifaciens ).
4. Use of the bacteriophage according to claim 1 or the compound according to claim 2 in the preparation of a pseudomonas antibacterial agent, wherein the pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas nigromatophila.
5. Use of the bacteriophage according to claim 1 or the compound according to claim 2 for non-therapeutic in vitro inhibition of Pseudomonas, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas melanogenes.
6. Use of the bacteriophage according to claim 1 or the compound according to claim 2 in the preparation of a feed additive for antagonizing Pseudomonas, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens and / or Pseudomonas melanogenes.
7. The use according to claim 3, 4 or 5, wherein the Pseudomonas aeruginosa is preferably carbapenem-resistant Pseudomonas aeruginosa.
